FDA approves J&J’s nasal spray for severe depression as stand-alone treatment
Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant depression. This marks a significant advancement in depression treatment as Spravato can provide rapid and durable symptom relief. The drug, available only under strict medical supervision, addresses symptoms quickly, enhancing patient well-being.
Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant depression. This marks a significant advancement in depression treatment as Spravato can provide rapid and durable symptom relief. The drug, available only under strict medical supervision, addresses symptoms quickly, enhancing patient well-being.
